Comparing of Spero Therapeutics Inc. (SPRO) and Trillium Therapeutics Inc. (NASDAQ:TRIL)

As Biotechnology companies, Spero Therapeutics Inc. (NASDAQ:SPRO) and Trillium Therapeutics Inc. (NASDAQ:TRIL) are our subject to compare. And more specifically their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Spero Therapeutics Inc. 11 -0.15 12.36M -2.18 0.00
Trillium Therapeutics Inc. N/A 0.00 21.61M -2.55 0.00

Table 1 highlights Spero Therapeutics Inc. and Trillium Therapeutics Inc.’s gross revenue, earnings per share and valuation.


Table 2 shows the return on equity, return on assets and net margins of the two firms.

Net Margins Return on Equity Return on Assets
Spero Therapeutics Inc. 114,338,575.39% -34.5% -31.2%
Trillium Therapeutics Inc. 7,571,829,011.91% 0% 0%

Analyst Recommendations

The table given features the ratings and recommendations for Spero Therapeutics Inc. and Trillium Therapeutics Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Spero Therapeutics Inc. 0 0 1 3.00
Trillium Therapeutics Inc. 0 0 0 0.00

Spero Therapeutics Inc.’s upside potential currently stands at 207.83% and an $35 consensus target price.

Institutional and Insider Ownership

Spero Therapeutics Inc. and Trillium Therapeutics Inc. has shares held by institutional investors as follows: 53.1% and 40.67%. Insiders held roughly 23.71% of Spero Therapeutics Inc.’s shares. Comparatively, insiders own roughly 0.26% of Trillium Therapeutics Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Spero Therapeutics Inc. -0.95% -11.87% -4.77% 9.14% -5.63% 68.94%
Trillium Therapeutics Inc. -1.69% 4.05% -38.77% -80.06% -93.02% -79.59%

For the past year Spero Therapeutics Inc. had bullish trend while Trillium Therapeutics Inc. had bearish trend.


Trillium Therapeutics Inc. beats on 6 of the 11 factors Spero Therapeutics Inc.

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. It is developing SPR994, an oral carbapenem-class antibiotic for use in adults to treat MDR gram-negative infections; SPR741 that has completed Phase I clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic that is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The companyÂ’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.